Form 4: Quest Diagnostics EVP Catherine Doherty Reports Stock Sales

Catherine T. Doherty, EVP at Quest Diagnostics, reports the sale of company stock to cover tax obligations and pursuant to a pre-arranged Rule 10b5-1 sales plan.

Summary

• Catherine T. Doherty, an Executive Vice President at Quest Diagnostics, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On February 19, 2025, she sold 535 shares of common stock at a price of $169.71 per share to cover tax withholding obligations related to vesting restricted stock units.
• On February 20, 2025, she sold 899 shares of common stock at a price of $170.99 per share, executed under a Rule 10b5-1 sales plan.
• Following these transactions, Doherty directly owns 70,457 shares of Quest Diagnostics common stock.
• She also indirectly owns 4,428 shares through the company's 401(k) and Supplemental Deferred Compensation Plan (SDCP).

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning or diversification strategies. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they perceive it as a lack of confidence in the company, although sales under a 10b5-1 plan are generally viewed as less concerning.

Key Dates

Keywords

Form 4, Quest Diagnostics, DGX, insider trading, Catherine T. Doherty, stock sale, Rule 10b5-1, executive compensation, beneficial ownership